A detailed history of Jacobs Levy Equity Management, Inc transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 576,447 shares of TBPH stock, worth $5.52 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
576,447
Previous 586,614 1.73%
Holding current value
$5.52 Million
Previous $4.97 Million 6.59%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.66 - $10.25 $77,879 - $104,211
-10,167 Reduced 1.73%
576,447 $4.65 Million
Q2 2024

Aug 14, 2024

BUY
$8.29 - $9.92 $237,450 - $284,138
28,643 Added 5.13%
586,614 $4.97 Million
Q1 2024

May 15, 2024

BUY
$8.22 - $11.59 $1.35 Million - $1.9 Million
163,951 Added 41.61%
557,971 $5 Million
Q4 2023

Feb 14, 2024

SELL
$8.58 - $11.4 $115,872 - $153,957
-13,505 Reduced 3.31%
394,020 $4.43 Million
Q3 2023

Nov 16, 2023

SELL
$8.38 - $10.44 $1.59 Million - $1.98 Million
-190,039 Reduced 31.8%
407,525 $3.52 Million
Q2 2023

Aug 14, 2023

SELL
$10.16 - $11.92 $4.2 Million - $4.92 Million
-413,125 Reduced 40.88%
597,564 $6.18 Million
Q1 2023

May 15, 2023

SELL
$9.87 - $11.44 $213,438 - $247,390
-21,625 Reduced 2.09%
1,010,689 $11 Million
Q4 2022

Feb 14, 2023

BUY
$9.65 - $11.34 $1.97 Million - $2.32 Million
204,408 Added 24.69%
1,032,314 $11.6 Million
Q3 2022

Nov 15, 2022

SELL
$8.39 - $10.22 $265,963 - $323,974
-31,700 Reduced 3.69%
827,906 $8.4 Million
Q2 2022

Aug 15, 2022

SELL
$8.41 - $10.34 $1.53 Million - $1.89 Million
-182,348 Reduced 17.5%
859,606 $7.79 Million
Q1 2022

May 16, 2022

BUY
$8.33 - $12.96 $158,486 - $246,576
19,026 Added 1.86%
1,041,954 $9.96 Million
Q4 2021

Feb 14, 2022

BUY
$7.42 - $11.05 $2.8 Million - $4.17 Million
377,051 Added 58.38%
1,022,928 $11.3 Million
Q3 2021

Nov 15, 2021

BUY
$6.77 - $14.41 $367,969 - $783,226
54,353 Added 9.19%
645,877 $4.78 Million
Q2 2021

Aug 16, 2021

BUY
$14.52 - $22.46 $458,977 - $709,960
31,610 Added 5.65%
591,524 $8.59 Million
Q1 2021

May 17, 2021

SELL
$16.57 - $21.08 $99,850 - $127,028
-6,026 Reduced 1.06%
559,914 $11.4 Million
Q4 2020

Feb 16, 2021

SELL
$14.89 - $20.16 $357,300 - $483,759
-23,996 Reduced 4.07%
565,940 $10.1 Million
Q3 2020

Nov 16, 2020

BUY
$14.79 - $22.49 $1.51 Million - $2.29 Million
101,829 Added 20.86%
589,936 $8.72 Million
Q2 2020

Aug 17, 2020

BUY
$20.64 - $30.69 $1.47 Million - $2.18 Million
71,165 Added 17.07%
488,107 $10.2 Million
Q1 2020

May 15, 2020

SELL
$17.84 - $31.21 $636,406 - $1.11 Million
-35,673 Reduced 7.88%
416,942 $9.64 Million
Q4 2019

Feb 14, 2020

BUY
$16.12 - $25.89 $1.15 Million - $1.84 Million
71,060 Added 18.62%
452,615 $11.7 Million
Q3 2019

Nov 14, 2019

BUY
$16.51 - $23.78 $1.18 Million - $1.7 Million
71,682 Added 23.13%
381,555 $7.43 Million
Q2 2019

Aug 13, 2019

BUY
$15.6 - $25.15 $640,536 - $1.03 Million
41,060 Added 15.27%
309,873 $5.06 Million
Q1 2019

May 14, 2019

BUY
$22.57 - $28.15 $2.12 Million - $2.65 Million
94,070 Added 53.83%
268,813 $6.09 Million
Q4 2018

Feb 14, 2019

BUY
$22.52 - $35.07 $91,881 - $143,085
4,080 Added 2.39%
174,743 $4.47 Million
Q3 2018

Nov 14, 2018

SELL
$22.83 - $32.67 $620,017 - $887,251
-27,158 Reduced 13.73%
170,663 $5.58 Million
Q2 2018

Aug 14, 2018

BUY
$22.06 - $25.52 $2.81 Million - $3.25 Million
127,422 Added 181.0%
197,821 $4.49 Million
Q1 2018

May 15, 2018

BUY
$23.37 - $29.71 $1.28 Million - $1.63 Million
54,899 Added 354.19%
70,399 $1.71 Million
Q4 2017

Feb 13, 2018

BUY
$25.82 - $35.66 $400,210 - $552,730
15,500
15,500 $432,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $639M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.